Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilars and to the discovery and development of novel therapeutics for autoimmune indications.
In July 2010, Momenta’s lead product (developed in collaboration with Sandoz) was approved as the first generic version of LOVENOX® (Enoxaparin Sodium Injection). In April 2015, the company announced the FDA approval of once daily Glatopa® 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of COPAXONE® 20 mg/mL. Glatopa was also developed in collaboration with Sandoz. The company's development pipeline includes a biosimilar version of HUMIRA® (adalimumab), a biosimilar version of ORENCIA® (abatacept) and a portfolio of five other early stage biosimilar programs in collaboration with Mylan and three novel drug candidates for autoimmune indications.
Feb 20, 2018
Copyright Nasdaq. Minimum 15 minutes delayed.
Events & Presentations
Feb 21, 2018 at 10:00 AM EST
Momenta Fourth Quarter 2017 Earnings Call
Feb 15, 2018 at 10:00 AM EST
LEERINK Partners 7th Annual Global Healthcare Conference
Jan 8, 2018 at 5:00 PM PST
The 36th Annual J. P. Morgan Healthcare Conference - Q&A session